Chronic Kidney Disease Plasma

About Chronic Kidney Disease Plasma

Chronic Kidney Disease Plasma for Nephrology and Cardiometabolic Research

Chronic Kidney Disease (CKD) Plasma is collected from IRB-consented donors with a clinically confirmed CKD diagnosis and processed within one day of collection to preserve cytokines, proteins and metabolites. CKD is a progressive loss of kidney function driven most often by diabetes, hypertension or primary glomerular disease — not by autoimmunity — and the resulting retention of solutes reshapes systemic metabolism, mineral handling and vascular biology. This plasma supports biomarker discovery, disease-progression research and therapeutic development.

Why Plasma for Chronic Kidney Disease

CKD is defined and staged by what circulates: reduced glomerular filtration means the plasma compartment directly reflects the failing organ. Anticoagulated plasma is the preferred matrix wherever platelet activation and clot formation would distort the analyte of interest.

• Filtration and injury markers — creatinine, urea and cystatin C are measured directly in plasma, allowing eGFR-based staging to be reconciled against experimental markers of tubular injury.
• Uremic retention solutes — protein-bound solutes such as indoxyl sulfate and p-cresyl sulfate accumulate as filtration falls and are studied as drivers of vascular and cardiac injury; they require a well-controlled, promptly processed matrix.
• Mineral and bone axis — FGF23, PTH, phosphate and vitamin D metabolites shift early and progressively in CKD, and are central to CKD-mineral bone disorder research.
• Anemia axis — erythropoietin, hepcidin and iron indices explain the anemia of CKD and underpin research on HIF-stabilising and ESA therapies.
• Chronic low-grade inflammation — IL-6, TNF receptors and CRP are consistently elevated as function declines and link CKD to its dominant cardiovascular risk.
• Plasma-specific assays — cell-free DNA, coagulation and complement analytes, and untargeted metabolomics are compromised in serum by clotting-cascade activation and platelet release, making EDTA or citrate plasma the correct choice.

Donor Stratification Available

• KDIGO eGFR category (G1 through G5) and albuminuria category where recorded
• Dialysis status: non-dialysis CKD, hemodialysis, peritoneal dialysis, or post-transplant
• Primary etiology: diabetic kidney disease, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidney disease
• Treatment status: RAAS inhibitor, SGLT2 inhibitor, phosphate binder, erythropoiesis-stimulating agent, or treatment-naive
• Cardiometabolic comorbidities: type 2 diabetes, hypertension, heart failure, obesity
• Matched healthy controls available, age- and sex-matched on request

Product Features

• Research Use Only (RUO)
• Chronic Kidney Disease plasma collected from clinically confirmed donors
• Processed within one day of collection
• Anticoagulant of choice (EDTA, sodium citrate, heparin) available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request; volumes and lot values reported per lot

De-identified Donor Data

• Verified CKD diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies and comorbidities
• Laboratory values including eGFR and creatinine where available
• Additional CKD-specific metadata available on request

Applications

• Biomarker discovery and validation for CKD progression and prognosis
• Uremic solute and untargeted metabolomics studies
• CKD-mineral bone disorder research (FGF23, PTH, phosphate axis)
• Anemia of CKD research including hepcidin and iron regulation
• Cytokine and inflammation profiling linking CKD to cardiovascular risk
• Proteomic and multiplex immunoassay panel development
• Cell-free DNA and coagulation or complement analyte studies
• Therapeutic response and drug-development research

Other Chronic Kidney Disease Specimen Types

• Chronic Kidney Disease Serum
• Chronic Kidney Disease Whole Blood
• Chronic Kidney Disease PBMC
• Chronic Kidney Disease Leukopak
• Diabetic Nephropathy Whole Blood

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Chronic Kidney Disease plasma is available in standard and custom volumes. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or documentation requirements to ensure compatibility with your country’s regulations. To browse availability across all disease states, visit our human plasma page.